Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Fcμ-Receptor (FcμR; TOSO/ FAIM3 ) Mediated Internalization of Antibody-Drug Conjugates: A Novel Approach to Selectively Target Chronic Lymphocytic Leukemia Cells

Berengere Vire, Ph.D., Alexandre David, Ph.D., Joshua D Thomas, Ph.D., Terrence R Burke, Jr., Ph.D., Christoph Rader, Ph.D., Adrian Wiestner, MD, PhD

Blood (2011) 118 (21): 734.

https://doi.org/10.1182/blood.V118.21.734.734

Published: 2011

Journal Articles

FcμR (TOSO/ FAIM3 ) Is An O-Glycosylated Endocytic Receptor That Shuttles IgM From the Cell Surface to the Lysosome and Whose Expression Is Regulated by TLR Signaling

Berengere Vire, Ph.D., Alexandre David, Ph.D., Adrian Wiestner, MD, PhD

Blood (2011) 118 (21): 2828.

https://doi.org/10.1182/blood.V118.21.2828.2828

Published: 2011

Journal Articles

The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia

Blood (2011) 117 (2): 563–574.

https://doi.org/10.1182/blood-2010-05-284984

Published: 2011

Includes: Supplemental data

Journal Articles

Loss of CD20 Expression and Exhaustion of Effector Cells Limit ADCC in CLL Patients Treated with Rituximab.

Berengere Vire, PhD, Justin SA Perry, BA, Elinor Lee, BS, Lawrence S Stennett, BS, Leigh Samsel, Philip McCoy, PhD, Wyndham H Wilson, MD, PhD, Bibiana Bielekova, MD, Adrian Wiestner, MD, PhD

Blood (2009) 114 (22): 1610.

https://doi.org/10.1182/blood.V114.22.1610.1610

Published: 2009

Journal Articles

Comparative Gene Expression Profiling of Leukemia Cells in Peripheral Blood and Tissue Compartments Reveals a Prominent Role of the Microenvironment for CLL Cell Proliferation.

Yair Herishanu, MD, Patricia Perez-Gelen, PhD, Delong Liu, PhD, Angelique Biancotto, PhD, Berengere Vire, PhD, Federica Gibellini, PhD, Ndegwa Njuguna, MD, Philip McCoy, PHD, Stefania Pittaluga, MD, Maryalice Stettler-Stevenson, Peter J Munson, PhD, Wyndham H Wilson, MD, PhD, Adrian Wiestner, MD, PhD

Blood (2009) 114 (22): 355.

https://doi.org/10.1182/blood.V114.22.355.355

Published: 2009

Journal Articles

High Incidence of Autoimmune Complications during Combined Fludarabine and Rituximab Therapy in CLL: Rapid Clearance of Rituximab as a Contributing Factor

Ndegwa Njuguna, MD, Paul V Beum, PhD, Berengere Vire, PhD, Gerald E Marti, MD, PhD, Therese White, RN, Wyndham H. Wilson, MD, PhD, Ronald P Taylor, PhD, Adrian Wiestner, MD, PhD

Blood (2008) 112 (11): 4208.

https://doi.org/10.1182/blood.V112.11.4208.4208

Published: 2008

Journal Articles

Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR-1) Is Expressed in Low Grade NHL and B-CLL and Activates the Non Canonical Wnt Pathway

Federica Gibellini, PhD, Colby M Chapman, BS, Yair Herishanu, MD, Berengere Vire, PhD, Keyvan Keyvanfar, Ndegwa Njuguna, MD, Adrian Wiestner, MD, PhD

Blood (2008) 112 (11): 3748.

https://doi.org/10.1182/blood.V112.11.3748.3748

Published: 2008

Journal Articles

The Role of the Microenvironment for CLL Proliferation and Survival: Gene Expression Profiling of Leukemic Cells Derived from Blood, Bone Marrow and Lymph Nodes Reveals the B-Cell Receptor and NF κB as Dominant Signaling Pathways

Yair Herishanu, MD, Berengere Vire, PhD, Delong Liu, PhD, Federica Gibellini, PhD, Gerald E Marti, MD, PhD, Therese White, RN, Ndegwa Njuguna, MD, Nalini Raghavachari, PhD, Poching Liu, PhD, Stefania Pittaluga, MD, PhD, Peter J Munson, PhD, Wyndham H. Wilson, MD, PhD, Adrian Wiestner, MD, PhD

Blood (2008) 112 (11): 356.

https://doi.org/10.1182/blood.V112.11.356.356

Published: 2008

Journal Articles

Lenalidomide Induced Cytokine Release Syndrome in Chronic Lymphocytic Leukemia (CLL): Clinical and Laboratory Correlates of Immune Activation.

Georg Aue, MD, Ndegwa Njuguna, MD, Xin Tian, PhD, Janet Valdez, PA, Susan Soto, RN, J. Philip McCoy, Jr., PhD, Leigh Samsel, Berengere Vire, PhD, Keyvan Keyvanfar, Stefania Pittaluga, MD, Adrian Wiestner, MD, PhD

Blood (2008) 112 (11): 2099.

https://doi.org/10.1182/blood.V112.11.2099.2099

Published: 2008

Journal Articles

Molecular Effects of Rituximab on CLL Cells In Vivo : Rapid Increase in Serum Interferon gamma, Induction of a Distinct Tumor Cell Gene Expression Signature and Loss of CD20 Expression.

Adrian Wiestner, MD, PhD, Elinor Lee, BA, Berengere Vire, PhD, Federica Gibellini, PhD, Ndegwa Njuguna, MD, Yair Herishanu, MD, Delong Liu, PhD, Peter Munson, PhD, Nalini Raghavachari, PhD, Therese White, RN, Gerald E. Marti, MD, PhD, Wyndham H. Wilson, MD, PhD

Blood (2007) 110 (11): 2048.

https://doi.org/10.1182/blood.V110.11.2048.2048

Published: 2007

NARROW

Fcμ-Receptor (FcμR; TOSO/ FAIM3 ) Mediated Internalization of Antibody-Drug Conjugates: A Novel Approach to Selectively Target Chronic Lymphocytic Leukemia Cells

FcμR (TOSO/ FAIM3 ) Is An O-Glycosylated Endocytic Receptor That Shuttles IgM From the Cell Surface to the Lysosome and Whose Expression Is Regulated by TLR Signaling

The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia

Loss of CD20 Expression and Exhaustion of Effector Cells Limit ADCC in CLL Patients Treated with Rituximab.

Comparative Gene Expression Profiling of Leukemia Cells in Peripheral Blood and Tissue Compartments Reveals a Prominent Role of the Microenvironment for CLL Cell Proliferation.

High Incidence of Autoimmune Complications during Combined Fludarabine and Rituximab Therapy in CLL: Rapid Clearance of Rituximab as a Contributing Factor

Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR-1) Is Expressed in Low Grade NHL and B-CLL and Activates the Non Canonical Wnt Pathway

The Role of the Microenvironment for CLL Proliferation and Survival: Gene Expression Profiling of Leukemic Cells Derived from Blood, Bone Marrow and Lymph Nodes Reveals the B-Cell Receptor and NF κB as Dominant Signaling Pathways

Lenalidomide Induced Cytokine Release Syndrome in Chronic Lymphocytic Leukemia (CLL): Clinical and Laboratory Correlates of Immune Activation.

Molecular Effects of Rituximab on CLL Cells In Vivo : Rapid Increase in Serum Interferon gamma, Induction of a Distinct Tumor Cell Gene Expression Signature and Loss of CD20 Expression.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only